194 related articles for article (PubMed ID: 15952408)
1. Idiopathic primary hyperaldosteronism: normalization of plasma aldosterone after one month withdrawal of long-term therapy with aldosterone-receptor antagonist potassium canrenoate.
Armanini D; Scaroni C; Mattarello MJ; Fiore C; Albiger N; Sartorato P
J Endocrinol Invest; 2005 Mar; 28(3):236-40. PubMed ID: 15952408
[TBL] [Abstract][Full Text] [Related]
2. Effects of Mineralocorticoid and AT1 Receptor Antagonism on The Aldosterone-Renin Ratio In Primary Aldosteronism-the EMIRA Study.
Rossi GP; Ceolotto G; Rossitto G; Maiolino G; Cesari M; Seccia TM
J Clin Endocrinol Metab; 2020 Jun; 105(6):. PubMed ID: 32067030
[TBL] [Abstract][Full Text] [Related]
3. Suppression of surgical hyperaldosteronism by potassium canrenoate during gynecologic surgery under sevoflurane anesthesia.
Watanabe T; Ogawa R
Acta Anaesthesiol Scand; 2000 Jul; 44(6):758-62. PubMed ID: 10903022
[TBL] [Abstract][Full Text] [Related]
4. Spontaneous resolution of idiopathic aldosteronism after long-term treatment with potassium canrenoate.
Armanini D; Fiore C; Pellati D
Hypertension; 2007 Oct; 50(4):e69-70. PubMed ID: 17709652
[No Abstract] [Full Text] [Related]
5. Some considerations about evolution of idiopathic primary aldosteronism.
Armanini D; Fiore C
J Endocrinol Invest; 2009 Jul; 32(7):623-5. PubMed ID: 19893360
[TBL] [Abstract][Full Text] [Related]
6. Mineralocorticoid Receptor Antagonist Effect on Aldosterone to Renin Ratio in Patients With Primary Aldosteronism.
Pecori A; Buffolo F; Burrello J; Mengozzi G; Rumbolo F; Avataneo V; D'Avolio A; Rabbia F; Bertello C; Veglio F; Mulatero P; Monticone S
J Clin Endocrinol Metab; 2021 Aug; 106(9):e3655-e3664. PubMed ID: 33942084
[TBL] [Abstract][Full Text] [Related]
7. Normokalemic hyperaldosteronism in patients with resistant hypertension.
Benchetrit S; Bernheim J; Podjarny E
Isr Med Assoc J; 2002 Jan; 4(1):17-20. PubMed ID: 11802302
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic value of calcium antagonists in autonomous hyperaldosteronism.
Stimpel M; Ivens K; Volkmann HP; Wambach G; Kaufmann W
Klin Wochenschr; 1989 Feb; 67(4):248-52. PubMed ID: 2648061
[TBL] [Abstract][Full Text] [Related]
9. The effect of amiloride on the renin-aldosterone system in primary hyperaldosteronism and Bartter's syndrome.
Griffing GT; Aurecchia SA; Sindler BH; Melby JC
J Clin Pharmacol; 1982; 22(11-12):505-12. PubMed ID: 6761369
[TBL] [Abstract][Full Text] [Related]
10. [Diagnosis and treatment outcome in primary aldosteronism based on a retrospective analysis of 187 cases].
Szücs N; Gláz E; Varga I; Tóth M; Kiss R; Patócs A; Jakab C; Perner F; Járay J; Horányi J; Dabasi G; Molnár F; Major L; Füto L; Rácz K; Tulassay Z
Orv Hetil; 2006 Jan; 147(2):51-9. PubMed ID: 16509213
[TBL] [Abstract][Full Text] [Related]
11. Are calcium antagonists helpful in the management of primary aldosteronism?
Stimpel M; Ivens K; Wambach G; Kaufmann W
J Cardiovasc Pharmacol; 1988; 12 Suppl 6():S131-4. PubMed ID: 2468897
[TBL] [Abstract][Full Text] [Related]
12. Effects of mineralocorticoid and AT-1 receptor antagonism on the aldosterone-renin ratio (ARR) in primary aldosteronism patients (EMIRA Study): rationale and design.
Rossitto G; Cesari M; Ceolotto G; Maiolino G; Seccia TM; Rossi GP
J Hum Hypertens; 2019 Feb; 33(2):167-171. PubMed ID: 30518805
[TBL] [Abstract][Full Text] [Related]
13. Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors.
Weir MR; Bakris GL; Gross C; Mayo MR; Garza D; Stasiv Y; Yuan J; Berman L; Williams GH
Kidney Int; 2016 Sep; 90(3):696-704. PubMed ID: 27350174
[TBL] [Abstract][Full Text] [Related]
14. [The effect of trilostane, a new inhibitor of adrenal steroid biosynthesis, on blood pressure, plasma aldosterone and other steroid hormones, serum potassium and plasma renin activity in primary aldosteronism (author's transl)].
Shigetomi S; Fukuchi S; Haruyama K; Yamazaki M
Nihon Naibunpi Gakkai Zasshi; 1982 Mar; 58(3):184-98. PubMed ID: 6212269
[TBL] [Abstract][Full Text] [Related]
15. Salt intake in mineralocorticoid receptor antagonist-treated primary aldosteronism: foe or ally?
Fountoulakis S; Papanastasiou L; Voulgaris N; Kounadi T; Markou A; Chrousos GP; Piaditis G
Hormones (Athens); 2020 Jun; 19(2):223-232. PubMed ID: 31863347
[TBL] [Abstract][Full Text] [Related]
16. Primary Hyperaldosteronism: Approach to Diagnosis and Management.
El-Asmar N; Rajpal A; Arafah BM
Med Clin North Am; 2021 Nov; 105(6):1065-1080. PubMed ID: 34688415
[TBL] [Abstract][Full Text] [Related]
17. The therapeutic use of a new potassium-sparing diuretic, amiloride, and a converting enzyme inhibitor, MK-421, in preventing hypokalemia associated with primary and secondary hyperaldosteronism.
Griffing GT; Melby JC
Clin Exp Hypertens A; 1983; 5(6):779-801. PubMed ID: 6309436
[TBL] [Abstract][Full Text] [Related]
18. [Differences of blood plasma renin activity, angiotensin II and aldosterone levels in essential or secondary hypertension].
Song AL; Zeng ZP; Tong AL; Lu L; Chen S; Li M; Fu CL; Wang YH; Sun ML
Zhonghua Nei Ke Za Zhi; 2012 Apr; 51(4):294-8. PubMed ID: 22781950
[TBL] [Abstract][Full Text] [Related]
19. A Patient with Bilateral Primary Aldosteronism Refractory to Oral Eplerenone Who Responded to Esaxerenone with Increased Renin Activity.
Okamura K; Matsushima M; Yamamoto F; Takamiya Y; Okuda T; Shirai K; Okamura K; Urata H
Am J Case Rep; 2020 Jan; 21():e920615. PubMed ID: 31907345
[TBL] [Abstract][Full Text] [Related]
20. Primary aldosteronism: considerations about the evaluation of the aldosterone to renin ratio during canrenone treatment.
Armanini D; Sabbadin C; Boscaro M
J Endocrinol Invest; 2021 Sep; 44(9):2009-2010. PubMed ID: 33454931
[No Abstract] [Full Text] [Related]
[Next] [New Search]
